UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
deCODE Announces Positive Results from Preliminary Phase II Clinical Trial of CEP-1347 in Asthma
June 24, 2006 deCODE genetics (Nasdaq:DCGN) today announced positive results from its preliminary Phase II clinical trial (Phase IIa) of Cephalon Inc.’s (Nasdaq: CEPH) CEP-1347 in asthma. Data on patients receiving active drug in the trial were consistent with a...
deCODE Study Links Gene Variant to Risk of Breast Cancer
June 20, 2006 A population-based study by a team of deCODE scientists and colleagues at Iceland’s National University Hospital published today provides a detailed look at the impact of a gene variant on risk of breast cancer. The variant is within a gene called BARD1...
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.